NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Pfizer Inc. PFE
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY15 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$62.6B
▼ 1.6% vs FY2024
Dividend streak
15 yrs
Raised every year since 2011
EPS · FY25
$1.36
Dividend / sh · FY25
$1.72
Payout · FY25
—
ROE · FY25
8.9%
Net margin · FY25
12.4%
Dividend coverage
0.8×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 62.6B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
12 cents of every revenue dollar became profit this year.
Per share
USD 1.36
Diluted EPS, FY2025
EPS
Dividend
Earnings covered only a fraction of the dividend — the rest came from cash or borrowing.
Profitability
8.9%
Return on equity, FY2025
ROE
Operating margin12.0%
Net margin12.4%
Return on assets3.7%
Each USD of equity produced 9 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises15 years
Growth
+8.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−14.8%
+8.5%
+2.5%
−0.3%
Net income
−37.2%
−3.2%
+1.1%
−0.4%
EPS, diluted
−37.1%
−3.6%
+2.1%
+1.9%
Dividend / share
+2.2%
+2.4%
+4.4%
+6.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 208.2B
total assets, end of FY2025
Total assetsUSD 208.2B
EquityUSD 86.5B
CashUSD 1.1B
Gross debtUSD 64.6B
Net debtUSD 63.5B
Current ratio1.16×
Net debt stands at 73% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
62.6
63.6
59.6
101.2
73.6
41.7
40.9
40.8
52.5
52.8
48.9
49.6
51.6
54.7
61.0
65.2
49.3
48.3
48.4
Operating income $B
7.5
8.0
1.1
34.7
24.3
7.0
11.3
3.6
12.3
8.4
9.0
12.2
15.7
11.2
11.5
9.5
10.7
·
·
EBITDA $B
14.1
15.0
7.3
39.8
29.5
11.7
17.1
10.0
18.6
14.1
14.1
17.8
22.0
18.6
20.2
17.9
15.4
·
·
Income tax $B
−0.3
−0.0
−1.1
3.3
1.9
0.4
0.6
−0.3
−9.0
1.1
2.0
3.1
4.3
2.2
3.6
1.2
2.1
1.6
1.0
Net income $B
7.8
8.0
2.1
31.4
22.0
9.2
16.0
11.2
21.3
7.2
7.0
9.1
22.0
14.6
10.0
8.3
8.6
8.1
8.1
EPS, diluted $
1.36
1.41
0.37
5.47
3.85
1.63
2.82
1.87
3.52
1.17
1.11
1.42
3.19
1.94
1.27
1.02
1.23
1.20
1.17
Dividend / sh $
1.72
1.69
1.65
1.61
1.57
1.53
1.46
1.38
1.30
1.22
1.12
1.04
0.96
0.88
0.80
0.72
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
8.9
9.1
2.3
36.3
31.3
14.5
25.3
16.6
32.6
11.6
10.2
12.4
27.9
17.8
11.8
9.3
11.7
14.1
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
55 of 55
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed